130 related articles for article (PubMed ID: 35598658)
1. Lactic acidosis promotes aggressive features of cholangiocarcinoma cells via upregulating ALDH1A3 expression through EGFR axis.
Thamrongwaranggoon U; Detarya M; Seubwai W; Saengboonmee C; Hino S; Koga T; Nakao M; Wongkham S
Life Sci; 2022 Aug; 302():120648. PubMed ID: 35598658
[TBL] [Abstract][Full Text] [Related]
2. High glucose upregulates FOXM1 expression via EGFR/STAT3 dependent activation to promote progression of cholangiocarcinoma.
Detarya M; Thaenkaew S; Seubwai W; Indramanee S; Phoomak C; Saengboonmee C; Wongkham S; Wongkham C
Life Sci; 2021 Apr; 271():119114. PubMed ID: 33513399
[TBL] [Abstract][Full Text] [Related]
3. Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor.
Obchoei S; Detarya M; Boonnate P; Saranaruk P; Vaeteewoottacharn K; Mahalapbutr P; Okada S; Wongkham S
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3379-3386. PubMed ID: 36308362
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
5. Lactic acidosis induces metabolic and phenotypic reprogramming in cholangiocarcinoma cells via the upregulation of thrombospondin-1.
Thamrongwaranggoon U; Kuribayashi K; Araki H; Hino Y; Koga T; Seubwai W; Wongkham S; Nakao M; Hino S
Cancer Sci; 2023 Apr; 114(4):1541-1555. PubMed ID: 36562400
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptotic cell death of cholangiocarcinoma cells by tiliacorinine from Tiliacora triandra: A mechanistic insight.
Detarya M; Mahalapbutr P; Waenphimai O; Kidoikhammouan S; Janeklang S; Sawanyawisuth K; Vaeteewoottacharn K; Seubwai W; Saengboonmee C; Thothaisong T; Pabuprapap W; Suksamrarn A; Wongkham S
Biochim Biophys Acta Gen Subj; 2023 Dec; 1867(12):130486. PubMed ID: 37813201
[TBL] [Abstract][Full Text] [Related]
7. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway.
Indramanee S; Sawanyawisuth K; Silsirivanit A; Dana P; Phoomak C; Kariya R; Klinhom-On N; Sorin S; Wongkham C; Okada S; Wongkham S
Sci Rep; 2019 Nov; 9(1):17266. PubMed ID: 31754244
[TBL] [Abstract][Full Text] [Related]
8. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
[TBL] [Abstract][Full Text] [Related]
9. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma.
Poosekeaw P; Pairojkul C; Sripa B; Sa Ngiamwibool P; Iamsaard S; Sakonsinsiri C; Thanan R; Ungarreevittaya P
PLoS One; 2021; 16(11):e0259075. PubMed ID: 34780466
[TBL] [Abstract][Full Text] [Related]
10. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.
Chen MH; Weng JJ; Cheng CT; Wu RC; Huang SC; Wu CE; Chung YH; Liu CY; Chang MH; Chen MH; Chiang KC; Yeh TS; Su Y; Yeh CN
Clin Cancer Res; 2016 Aug; 22(16):4225-35. PubMed ID: 27076629
[TBL] [Abstract][Full Text] [Related]
11. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Insulin Receptor Substrate 1 (IRS1) Relates to Poor Prognosis and Promotes Proliferation, Stemness, Migration, and Oxidative Stress Resistance in Cholangiocarcinoma.
Kaewlert W; Sakonsinsiri C; Lert-Itthiporn W; Ungarreevittaya P; Pairojkul C; Pinlaor S; Murata M; Thanan R
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768755
[TBL] [Abstract][Full Text] [Related]
13. The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines.
Samatiwat P; Tabtimmai L; Suphakun P; Jiwacharoenchai N; Toviwek B; Kukongviriyapan V; Gleeson MP; Choowongkomon K
Asian Pac J Cancer Prev; 2021 Feb; 22(2):381-390. PubMed ID: 33639651
[TBL] [Abstract][Full Text] [Related]
14. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
15. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase.
Klinhom-On N; Seubwai W; Sawanyawisuth K; Obchoei S; Mahalapbutr P; Wongkham S
Life Sci; 2021 Dec; 286():120072. PubMed ID: 34688691
[TBL] [Abstract][Full Text] [Related]
19. γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus.
Saengboonmee C; Sorin S; Sangkhamanon S; Chomphoo S; Indramanee S; Seubwai W; Thithuan K; Chiu CF; Okada S; Gingras MC; Wongkham S
World J Gastroenterol; 2023 Jul; 29(28):4416-4432. PubMed ID: 37576707
[TBL] [Abstract][Full Text] [Related]
20. Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells.
Waenphimai O; Mahalapbutr P; Vaeteewoottacharn K; Wongkham S; Sawanyawisuth K
Eur J Pharmacol; 2022 May; 922():174899. PubMed ID: 35337815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
